Data Insights

MEN-2312 by Stemline Therapeutics for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

MEN-2312 is under clinical development by Stemline Therapeutics and currently in Phase I for Human Epidermal Growth Factor Receptor 2...

Likelihood of Approval and Phase Transition Success Rate Model - MEN-2312 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

Data Insights

MEN-2312 by Stemline Therapeutics for Solid Tumor: Likelihood of Approval

MEN-2312 is under clinical development by Stemline Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - MEN-2312 in Solid Tumor

Data Insights

Tagraxofusp by Stemline Therapeutics for Chronic Myelomonocytic Leukemia (CMML): Likelihood of Approval

Tagraxofusp is under clinical development by Stemline Therapeutics and currently in Phase III for Chronic Myelomonocytic Leukemia (CMML). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Tagraxofusp in Chronic Myelomonocytic Leukemia (CMML)

Data Insights

Tagraxofusp by Stemline Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval

Tagraxofusp is under clinical development by Stemline Therapeutics and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Tagraxofusp in Myelodysplastic Syndrome

Data Insights

Tagraxofusp by Stemline Therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

Tagraxofusp is under clinical development by Stemline Therapeutics and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...

Likelihood of Approval and Phase Transition Success Rate Model - Tagraxofusp in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

Data Insights

Elacestrant hydrochloride by Stemline Therapeutics for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

Elacestrant hydrochloride is under clinical development by Stemline Therapeutics and currently in Phase III for Human Epidermal Growth Factor Receptor...

Likelihood of Approval and Phase Transition Success Rate Model - Elacestrant Hydrochloride in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

Data Insights

Tagraxofusp by Stemline Therapeutics for Hypereosinophilic Syndrome: Likelihood of Approval

Tagraxofusp is under clinical development by Stemline Therapeutics and currently in Phase II for Hypereosinophilic Syndrome. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Tagraxofusp in Hypereosinophilic Syndrome

Data Insights

Tagraxofusp by Stemline Therapeutics for Myelofibrosis: Likelihood of Approval

Tagraxofusp is under clinical development by Stemline Therapeutics and currently in Phase II for Myelofibrosis. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Tagraxofusp in Myelofibrosis

Data Insights

Tagraxofusp by Stemline Therapeutics for Systemic Mastocytosis: Likelihood of Approval

Tagraxofusp is under clinical development by Stemline Therapeutics and currently in Phase II for Systemic Mastocytosis. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Tagraxofusp in Systemic Mastocytosis

Data Insights

Tagraxofusp by Stemline Therapeutics for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

Tagraxofusp is under clinical development by Stemline Therapeutics and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to...

Data Insights

Tagraxofusp by Stemline Therapeutics for Refractory Acute Myeloid Leukemia: Likelihood of Approval

Tagraxofusp is under clinical development by Stemline Therapeutics and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...

Data Insights

Tagraxofusp by Stemline Therapeutics for Hypereosinophilic Syndrome: Likelihood of Approval

Tagraxofusp is under clinical development by Stemline Therapeutics and currently in Phase II for Hypereosinophilic Syndrome. According to GlobalData, Phase...

Data Insights

Tagraxofusp by Stemline Therapeutics for Myelofibrosis: Likelihood of Approval

Tagraxofusp is under clinical development by Stemline Therapeutics and currently in Phase II for Myelofibrosis. According to GlobalData, Phase II...

Data Insights

Tagraxofusp by Stemline Therapeutics for Systemic Mastocytosis: Likelihood of Approval

Tagraxofusp is under clinical development by Stemline Therapeutics and currently in Phase II for Systemic Mastocytosis. According to GlobalData, Phase...

Data Insights

MEN-1703 by Stemline Therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

MEN-1703 is under clinical development by Stemline Therapeutics and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...

Likelihood of Approval and Phase Transition Success Rate Model - MEN-1703 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

Data Insights

Izorlisib by Stemline Therapeutics for Metastatic Colorectal Cancer: Likelihood of Approval

Izorlisib is under clinical development by Stemline Therapeutics and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Izorlisib in Metastatic Colorectal Cancer

Data Insights

Izorlisib by Stemline Therapeutics for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

Izorlisib is under clinical development by Stemline Therapeutics and currently in Phase II for Human Epidermal Growth Factor Receptor 2...

Likelihood of Approval and Phase Transition Success Rate Model - Izorlisib in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

Data Insights

MEN-1703 by Stemline Therapeutics for Refractory Acute Myeloid Leukemia: Likelihood of Approval

MEN-1703 is under clinical development by Stemline Therapeutics and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...

Likelihood of Approval and Phase Transition Success Rate Model - MEN-1703 in Refractory Acute Myeloid Leukemia

Data Insights

MEN-1703 by Stemline Therapeutics for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

MEN-1703 is under clinical development by Stemline Therapeutics and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to...

Likelihood of Approval and Phase Transition Success Rate Model - MEN-1703 in Relapsed Acute Myeloid Leukemia